Top

Published in:

Open Access 01-12-2015 | Review of the literature

New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015–September 2015

Author: J. Han van Krieken

Published in: Journal of Hematopathology | Issue 4/2015

Excerpt

We are in the era of precision medicine, but I am not sure whether we are at the beginning, in the middle, or at the end. On the one hand, we have only a few targets in certain cancer types for which we have precise drugs, like the tyrosine kinase inhibition in chronic myeloid leukemia; on the other hand, it seems that targeting most cancers requires action towards several different pathways. This review indicates that our knowledge accumulates fast, but that simple solutions might not be expected anymore. Nevertheless, I do think that we are on the right path, but it will be a long one. …

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egilee C, van Oers MH, Eldering E, TKersten MJ, Kater AP (2015) The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. Leukemia. doi:https://doi.org/10.1038/leu.2015.241 PubMedCrossRef

Akhter A, Street L, Ghosh S, Burns BF, Elyamany G, Shabani-Rad MT, Stewart DA, Mansoor A (2015) Concomitant high expression of toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle celllymphoma. Hematol Oncol. doi:https://doi.org/10.1002/hon.2251 PubMedCrossRef

Linley A, Krysov S, Ponzoni M, Johnson PW, Packham G, Stevenson FK. Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. Blood. 2015.

Kridel R, Mottok A, Farinha P, Ben-Neriah S, Ennishi D, Zheng Y, Chavez EA, Shulha HP, Tan K, Chan FC, Boyle M, Meissner B, Telenius A, Sehn LH, Marra MA, Shah SP, Steidl C, Connors JM, Scott DW, Gascoyne RD. Cell-of-origin of transformed follicular lymphoma. Blood. 2015.

van den Brand M, Mathijssen JJ, Garcia-Garcia M, Hebeda KM, Groenen PJ, Falini B, Serrano S, van Krieken JH (2015) Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma—combined performance ofmultiple markers. Haematologica 100(9):e358–e360PubMedPubMedCentralCrossRef

van den Brand M, van Krieken JH (2013) Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. Haematologica 98(7):1003–1013PubMedPubMedCentralCrossRef

van den Brand M, van Krieken JH. Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation. Leukemia and Lymphoma 205, in press

Care MA, Westhead DR, Tooze RM (2015) Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma. Genome Med 7(1):96PubMedPubMedCentralCrossRef

Piccaluga PP, Navari M, Falco G, Ambrosio MR, Lazzi S, Fuligni F, Bellan C, Rossi M, Sapienza MR, Laginestra MA, Etebari M, Rogena EA, Tumwine L, Tripodo C, Gibellini D, Consiglio J, Croce C, Pileri SA, Leoncini L. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. Oncotarget. 2015.

10.

Wagener R, Aukema SM, Schlesner M, Haake A, Burkhardt B, Claviez A, Drexler HG, Hummel M, Kreuz M, Loeffler M, Rosolowski M, López C, Möller P, Richter J, Rohde M, Betts MJ, Russell RB, Bernhart SH, Hoffmann S, Rosenstiel P, Schilhabel M, Szczepanowski M, Trümper L, Klapper W, Siebert R (2015) ICGC MMML-Seq-Project; “Molecular Mechanisms in Malignant Lymphomas” Network Project of the Deutsche Krebshilfe. The PCBP1 gene encoding poly(rC) binding protein I is recurrently mutated in Burkitt lymphoma. Genes Chromosom Cancer 54(9):555–564PubMedCrossRef

11.

Doose G, Haake A, Bernhart SH, López C, Duggimpudi S, Wojciech F, Bergmann AK, Borkhardt A, Burkhardt B, Claviez A, Dimitrova L, Haas S, Hoell JI, Hummel M, Karsch D, Klapper W, Kleo K, Kretzmer H, Kreuz M, Küppers R, Lawerenz C, Lenze D, Loeffler M, Mantovani-Löffler L, Möller P, Ott G, Richter J, Rohde M, Rosenstiel P, Rosenwald A, Schilhabel M, Schneider M, Scholz I, Stilgenbauer S, Stunnenberg HG, Szczepanowski M, Trümper L, Weniger MA, ICGC MMML-Seq Consortium, Hoffmann S, Siebert R, Iaccarino I (2015) MINCR is a MYC-induced lncRNA able to modulate MYC’s transcriptional network in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 112(38):E5261–E5270PubMedPubMedCentralCrossRef

12.

Jain S, Chen J, Nicolae A, Wang H, Shin DM, Adkins EB, Sproule TJ, Leeth CM, Sakai T, Kovalchuk AL, Raffeld M, Ward JM, Rehg JE, Waldmann TA, Jaffe ES, Roopenian DC, Morse HC 3rd. IL-21-driven neoplasms in SJL mice mimic some key features of human angioimmunoblastic T-cell lymphoma. Am J Pathol. 2015. doi: https://doi.org/10.1016/j.ajpath.2015.07.021.PubMedPubMedCentralCrossRef

13.

Mitou G, Frentzel J, Desquesnes A, Le Gonidec S, AlSaati T, Beau I, Lamant L, Meggetto F, Espinos E, Codogno P, Brousset P, Giuriato S. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. Oncotarget. 2015.

14.

Glaser SL, Clarke CA, Keegan TH, Chang ET, Weisenburger DD (2015) Time trends in rates of Hodgkin lymphoma histologic subtypes: true incidence changes or evolving diagnostic practice? Cancer Epidemiol Biomark Prev 24(10):1474–1488CrossRef

15.

Kumarasinghe G, Lavee O, Parker A, Nivison-Smith I, Milliken S, Dodds A, Joseph J, Fay K, Ma DD, Malouf M, Plit M, Havryk A, Keogh AM, Hayward CS, Kotlyar E, Jabbour A, Glanville AR, Macdonald PS, Moore JJ (2015) Post-transplant lymphoproliferative disease in heart and lung transplantation: defining risk and prognostic factors. J Heart Lung Transplant. doi:https://doi.org/10.1016/j.healun.2015.05.021 PubMedCrossRef

16.

Yuan J, Wright G, Rosenwald A, Steidl C, Gascoyne RD, Connors JM, Mottok A, Weisenburger DD, Greiner TC, Fu K, Smith L, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Ott G, Vose JM, Staudt LM, Chan WC (2015) Lymphoma leukemia molecular profiling project (LLMPP). Identification of primary mediastinal large B-cell lymphoma at nonmediastinal sites by gene expression profiling. Am J Surg Pathol 39(10):1322–1330PubMedCrossRef

17.

Lu TX, Liang JH, Miao Y, Fan L, Wang L, Qu XY, Cao L, Gong QX, Wang Z, Zhang ZH, Xu W, Li JY (2015) Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep 5:12168PubMedPubMedCentralCrossRef

18.

Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH (2015) Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma—is it necessary? Oncotarget 6(16):13933–13945PubMedPubMedCentralCrossRef

19.

Agarwal R, Lade S, Liew D, Rogers TM, Byrne D, Feleppa F, Juneja S, Westerman DA (2015) Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases. J Clin Pathol. doi:https://doi.org/10.1136/jclinpath-2015-203002 PubMedCrossRef

20.

Fang JC, Xia ZX, Wang CN, Li Z. Clinicopathologic and immunophenotypic features of primary intestinal extranodal NK/T-cell lymphoma, nasal type. Int J Surg Pathol. 2015.

21.

Robson A, Shukur Z, Ally M, Kluk J, Liu K, Pincus L, Sahni D, Sundram U, Subtil A, Karai L, Kempf W, Schieke S, Coates P (2015) Immunocytochemical p63 expression discriminates between primary cutaneous follicle centre cell and diffuse large B-cell lymphoma-leg type, and is of the TAp63 isoform. Histopathology. doi:https://doi.org/10.1111/his.12855 PubMedCrossRef

22.

Akhter A, Mahe E, Street L, Pournazari P, Perizzolo M, Shabani-Rad MT, Stewart DA, Mansoor A (2015) CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series. J Clin Pathol 68(10):844–848PubMedCrossRef

23.

Ribera-Cortada I, Martinez D, Amador V, Royo C, Navarro A, Beà S, Gine E, de Leval L, Serrano S, Wotherspoon A, Colomer D, Martinez A, Campo E (2015) Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype. Mod Pathol. doi:https://doi.org/10.1038/modpathol.2015.99 PubMedCrossRef

24.

Magro CM, Momtahen S, Lee BA, Swanson DL, Pavlovic MD. Epidermotropic B-cell lymphoma: a unique subset of CXCR3-positive marginal zone lymphoma. Am J Dermatopathol. 2015.

25.

Deng L, Song Y, Young KH, Hu S, Ding N, Song W, Li X, Shi Y, Huang H, Liu W, Zheng W, Wang X, Xie Y, Lin N, Tu M, Ping L, Ying Z, Zhang C, Sun Y, Zhu J (2015) Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. Oncotarget 6(28):25061–25075PubMedPubMedCentralCrossRef

26.

Masqué-Soler N, Szczepanowski M, Kohler CW, Aukema SM, Nagel I, Richter J, Siebert R, Spang R, Burkhardt B, Klapper W (2015) Clinical and pathological features of Burkitt lymphoma showing expression of BCL2—an analysis including gene expression in formalin-fixed paraffin-embedded tissue. Br J Haematol. doi:https://doi.org/10.1111/bjh.13624 PubMedCrossRef

27.

Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, Jiang B, Rohr J, Cannon A, Steidl C, Fu K, Li Y, Hung S, Weisenburger DD, Greiner TC, Smith L, Ott G, Rogan EG, Staudt LM, Vose J, Iqbal J, Chan WC (2015) IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 126(15):1741–1752PubMedPubMedCentralCrossRef

28.

Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee CS, Mah A, Zehnder A, Ohgami R, Kulkarni S, Armstrong R, Weng WK, Gratzinger D, Tavallaee M, Rook A, Snyder M, Kim Y, Khavari PA (2015) Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nat Genet 47(9):1056–1060PubMedPubMedCentralCrossRef

29.

Önder E, Arıkök AT, Önder S, Han Ü, Sorar M, Kertmen H, Yılmaz ED, Fesli R, Alper M (2015) Corticosteroid pre-treated primary CNS lymphoma: a detailed analysis of stereotactic biopsy findings and consideration of interobserver variability. Int J Clin Exp Pathol 8(7):7798–7808PubMedPubMedCentral

30.

van Krieken JH (2015) New developments in the pathology of malignant lymphoma: a review of literature published from January 2015 to April 2015. J Hematop 8(2):71–79PubMedPubMedCentralCrossRef

31.

Cencini E, Fabbri A, Rigacci L, Lazzi S, Gini G, Cox MC, Mancuso S, Abruzzese E, Kovalchuk S, Goteri G, Di Napoli A, Bono R, Fratoni S, Di Lollo S, Bosi A, Leoncini L, Bocchia M (2015) Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment. Hematol Oncol. doi:https://doi.org/10.1002/hon.2249 PubMedCrossRef

32.

Lennerz JK, Hoffmann K, Bubolz AM, Lessel D, Welke C, Rüther N, Viardot A, Möller P. Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma. Oncotarget. 2015.

33.

Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16(9):1111–1122PubMedCrossRef

34.

Novak AJ, Asmann YW, Maurer MJ, Wang C, Slager SL, Hodge LS, Manske M, Price-Troska T, Yang ZZ, Zimmermann MT, Nowakowski GS, Ansell SM, Witzig TE, McPhail E, Ketterling R, Feldman AL, Dogan A, Link BK, Habermann TM, Cerhan JR (2015) Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. Blood Cancer J 5:e346. doi:https://doi.org/10.1038/bcj.2015.69 PubMedPubMedCentralCrossRef

35.

Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, Pan CM, Hu Y, Cai CP, Dong Y, Huang JY, Wang L, Shen Y, Meng G, Zhou JF, Hu JD, Wang JF, Liu YH, Yang LH, Zhang F, Wang JM, Wang Z, Peng ZG, Chen FY, Sun ZM, Ding H, Shi JM, Hou J, Yan JS, Shi JY, Xu L, Li Y, Lu J, Zheng Z, Xue W, Zhao WL, Chen Z, Chen SJ (2015) Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet 47(9):1061–1066PubMedCrossRef

36.

Okamoto A, Yanada M, Inaguma Y, Tokuda M, Morishima S, Kanie T, Yamamoto Y, Mizuta S, Akatsuka Y, Yoshikawa T, Mizoguchi Y, Nakamura S, Okamoto M, Emi N (2015) The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients. Hematol Oncol. doi:https://doi.org/10.1002/hon.2245 PubMedCrossRef

37.

Okamoto A, Yanada M, Miura H, Inaguma Y, Tokuda M, Morishima S, Kanie T, Yamamoto Y, Mizuta S, Akatsuka Y, Yoshikawa T, Mizoguchi Y, Nakamura S, Okamoto M, Emi N (2015) Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma. Cancer Sci. doi:https://doi.org/10.1111/cas.12812 PubMedPubMedCentralCrossRef

38.

Wong KK, Ch’ng ES, Loo SK, Husin A, Muruzabal MA, Møller MB, Pedersen LM, Pomposo MP, Gaafar A, Banham AH, Green TM, Lawrie CH (2015) Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. Exp Mol Pathol 99(3):537–545PubMedCrossRef

39.

Wang Y, Li YJ, Jiang WQ, Rao HL, Huang JJ, Xia Y, Bi X, Sun P, Huang HQ, Lin TY, Guan ZZ, Li ZM (2015) Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. Ann Hematol 94(11):1865–1873PubMedCrossRef

40.

Liu Z, Xu-Monette ZY, Cao X, Manyam GC, Wang X, Tzankov A, Xia Y, Li X, Visco C, Sun R, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, O’Malley DP, Medeiros LJ, Young KH (2015) Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod Pathol 28(10):1297–1314PubMedCrossRef

41.

Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T, Akashi K, Takayanagi R, Shiratsuchi M, Oshima K. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015.

42.

Wang XJ, Seegmiller AC, Reddy NM, Li S (2015) CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma. Eur J Haematol. doi:https://doi.org/10.1111/ejh.12680 PubMedCrossRef

43.

Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M (2015) Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR. J Mol Diagn 17(6):652–660PubMedCrossRef

44.

Hurabielle C, Ingen-Housz-Oro S, Ortonne N, Cornillet-Lefèbvre P, Merah A, D’Incan M, Joly P, Franck N, Estève E, Maubec E, Grange F, Machet L, Laroche L, Barete S, Dalac S, Mortier L, Michel C, Quereux G, Saiag P, Ram-Wolff C, Lenormand B, Wechsler J, Bastuji-Garin S, Bagot M, Delfau-Larue MH (2015) Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group. Br J Dermatol. doi:https://doi.org/10.1111/bjd.14017 PubMedCrossRef

45.

Deeb SJ, Tyanova S, Hummel M, Schmidt-Supprian M, Cox J, Mann M. Machine learning based classification of diffuse large B-cell lymphoma patients by their protein expression profiles. Mol Cell Proteomics. 2015.

46.

Insuasti-Beltran G, Gale JM, Wilson CS, Foucar K, Czuchlewski DR (2015) Significance of MYD88 L265P mutation status in the subclassification of low-grade B-cell lymphoma/leukemia. Arch Pathol Lab Med 139(8):1035–1041PubMedCrossRef

47.

Ryan RJ, Drier Y, Whitton H, Cotton MJ, Kaur J, Issner R, Gillespie S, Epstein CB, Nardi V, Sohani AR, Hochberg EP, Bernstein BE (2015) Detection of enhancer-associated rearrangements reveals mechanisms of oncogene dysregulation in B-cell lymphoma. Cancer Discov 5(10):1058–1071PubMedPubMedCentralCrossRef

48.

Sha C, Barrans S, Care MA, Cunningham D, Tooze RM, Jack A, Westhead DR (2015) Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas. Genome Med 7(1):64PubMedPubMedCentralCrossRef

49.

Yano T, van Krieken JH, Magrath IT, Longo DL, Jaffe ES, Raffeld M (1992) Histogenetic correlations between subcategories of small noncleaved cell lymphomas. Blood 79(5):1282–1290PubMed

50.

van Krieken JH, Raffeld M, Raghoebier S, Jaffe ES, van Ommen GJ, Kluin PM (1990) Molecular genetics of gastrointestinal non-Hodgkin’s lymphomas: unusual prevalence and pattern of c-myc rearrangements in aggressive lymphomas. Blood 76(4):797–800PubMed

Title: New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015–September 2015
Author: J. Han van Krieken
Publication date: 01-12-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Hematopathology / Issue 4/2015
Print ISSN: 1868-9256
Electronic ISSN: 1865-5785
DOI: https://doi.org/10.1007/s12308-015-0262-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015–September 2015

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2015

We are not our genes

Cerebellar EBV-associated diffuse large B cell lymphoma following angioimmunoblastic T cell lymphoma

‘Could it be mycosis fungoides?’: an approach to diagnosing patch stage mycosis fungoides

Molecular genetic data favoring a sequential clonal transformation of a large B cell lymphoma into an anaplastic large T cell lymphoma, ALK-negative

MicroRNA expression profiles in BCR-ABL-negative primary myelofibrosis with chromosome 7q defects